Tag: systemic inflammation

1. This phase III drug trial showed that dexamethasone does not significantly reduce risk of adverse events and death following major non-cardiac surgery. 2. Secondary safety outcomes were comparable between the dexamethasone and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Major surgery has potential major complications, such as shock, infection,...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...